PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA

BUD · Budget/Appropriations

Presidents Budget Fiscal Year 2027. Government funding policy issues.

CPT · Copyright/Patent/Trademark

Biopharmaceutical innovation policy issues. Biosimilar approval and reimbursement policy issues.

PHA · Pharmacy

User fee issues. Vaccine policy issues. Pharmacy Benefit Manager reform and policy issues. Drug cost and pricing policy issues. Most Favored Nation (MFN) policy issues. Drug importation policy issues. FDA policy issues. Competition policy issues. Orphan Drug Act policy issues. Antimicrobial resistance policy issues. Supply chain policy issues. 340B drug discount program rebate and policy issues. Drug shortages policy issues . Executive Order 14297: Delivering Most-Favored Nation Prescription Drug Pricing to American Patients. Executive Order 14273: Lowering Drug Prices by Once Again Putting Americans First. Biopharmaceutical innovation policy issues. Pricing and reimbursement policy issues. Inflation Reduction Act of 2022 (Public Law 117-169) implementation policy issues.

HCR · Health Issues

Patient assistance program policy issues.

MMM · Medicare/Medicaid

H.R.1: One Big Beautiful Bill Act (Public Law 119-21). Part D redesign and policy issues including non-interference and rebates policy issues. Part B policy issues. Drug cost and pricing policy issues. Medicare rebate policy issues. Center for Medicare and Medicaid Innovation (CMMI) policy issues. CMS IPAY Guidance on the Medicare Drug Price Negotiation Program. IPAY and Maximum Fair Prices policy issues. Medicaid rebate policy issues. GENErating cost Reductions for U.S. Medicaid (GENEROUS) model. Global Benchmark for Efficient Drug Pricing (GLOBE) Proposed Rule. Guarding U.S. Medicare Against Rising Drugs Costs (GUARD) Proposed Rule. IRA price negotiation expansion policy issues.

Literal federal measure citations: H.R.1

TRD · Trade (domestic/foreign)

Tariff policy issues.